Precision Neuroscience

Executive Summary

Precision Neuroscience is a medical device company developing a minimally invasive brain-computer interface (BCI) technology called the Layer 7 Cortical Interface. This high-resolution electrode array is designed to be placed on the brain's surface without damaging tissue, enabling real-time neural recording and stimulation. The company's mission is to restore function for millions of patients with neurological conditions such as paralysis, stroke, and neurodegenerative diseases. Unlike traditional BCIs that require penetrating electrodes, Precision's approach aims to combine high signal resolution with a lower risk profile, potentially accelerating clinical adoption. As a private company founded in 2021, Precision Neuroscience is still in early-stage development but has garnered attention for its innovative approach to bridging the gap between neural tissue and electronics. The company's technology could transform the treatment landscape for neurological disorders by enabling closed-loop neurostimulation and communication prosthetics. With a strong focus on safety and scalability, Precision Neuroscience is positioning itself as a key player in the emerging field of cortical interfaces, though it faces competition from other BCI developers like Neuralink and Synchron.

Upcoming Catalysts (preview)

• Q2 2026First-in-human clinical trial initiation60% success
• Q4 2026FDA breakthrough device designation70% success
• Q3 2026Series A funding round announcement80% success